British Society for Haematology. Listening. Learning. Leading British Society for Haematology. Listening. Learning. Leading
09 February 2018

Hybrid-capture sequencing should be the method of choice for sequencing actionable gene mutations across the most common forms of lymphoid cancer, according to a new analysis.

Researchers said the technique could identify relevant mutations in 91% of patients.

It can also be incorporated into routine diagnostic workflows because it can be applied to routinely-acquired formalin-fixed, paraffin-embedded tissues, the Canadian researchers reported yesterday in The Journal of Molecular Diagnostics.

The conclusions come from testing the assay on tissues from 219 patients with lymphoid cancers, treated in British Columbia, Canada, this decade.

Researcher Dr Christian Steidl, of the University of British Columbia, Vancouver, said: "To realise the benefits of the most recent progress in cancer genomics, clinical implementation of precision medicine approaches is needed in the form of novel biomarker assays.

“Fully implemented targeted sequencing-based assays in routine diagnostic pathology laboratories are currently lacking in lymphoid cancer care.

"Our findings demonstrate the feasibility and outline the clinical utility of integrating a lymphoma-specific pipeline into personalized cancer care."

The work was praised in a separate editorial in the journal.

Senior pathologist Dr Robert Ohgami, of Stanford University Medical Center, California, USA, said: "This study is remarkably comprehensive, which will help any molecular laboratory design and implement their own next-generation sequencing lymphoma panel using this work as a template.”

Source: Assessment of Capture and Amplicon-based Approaches for the Development of a Targeted Next-generation Sequencing Pipeline to Personalize Lymphoma Management The Journal of Molecular Diagnostics 8 February 2018

Link: http://jmd.amjpathol.org/article/S1525-1578(17)30425-7/fulltext

 

Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News http://www.englemed.co.uk/